A Phase 2 interventional study of Roxadustat in Chemotherapy Induced Anemia, sponsored by FibroGen. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-03.
Sponsored by FibroGen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.
Among the 43 studies testing roxadustat in Anemia, this one is the 30th largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 2, and was the 28th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:
Kyntra Bio
Ages 18+
Tianjin Medical University General Hospital
Ages 18–80
roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 2006; this study’s year is marked. 2 started in 2019.
This study's enrollment of 92 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 154 across the 43 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under FibroGen, one of the names counted as Kyntra Bio. Under that name alone:
FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.
21 studies in Anemia by Kyntra Bio: 1 open now, 1 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 21 studies in Anemia by Kyntra Bio, this one is the 16th largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 2, and was the 16th registered.
Kyntra Bio’s Anemia studies by the year they started, since 2006.
1 of the studies testing roxadustat in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies testing roxadustat in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kyntra Bio’s 21 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out if roxadustat (also known as FG-4592) is safe and effective for the treatment of anemia in participants receiving chemotherapy treatment for cancer.
This study consists of three periods:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 16 weeks.
Drug: Roxadustat
Roxadustat will be administered per schedule specified in the arm description.
Also known as: FG-4592
Maximum Change in Hb Within 16 Weeks From Baseline Without Red Blood Cell (RBC) Transfusion
Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1. All central lab assessments from Day 1 to end of treatment (EOT) or early termination (ET) were included in the evaluation of this endpoint. Hb values within 4 weeks after an RBC transfusion were excluded.
Time frame: Baseline, up to Week 16
Mean Change in Hb Level From Baseline to Week 16 (Without RBC Transfusion)
Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1. Mean Hb during treatment was computed using the mean area-under-the-curve trapezoid method, from Day 1 to EOT or ET Hb assessment.
Time frame: Baseline, Week 16
Change in Hb From Baseline at Weeks 9, 13, and 16 (Without RBC Transfusion)
Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1.
Time frame: Baseline, Weeks 9, 13, and 16
Percentage of Participants Who Achieved a ≥1 g/dL Increase in Hb From Baseline Through Week 16
The 95% confidence interval (CI) was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.
Time frame: Baseline through Week 16
Time to Achieve a ≥1 g/dL Increase in Hb From Baseline Through Week 16
Median was calculated using Kaplan-Meier product limit method. 95% CI was calculated using the method of Brookmeyer and Crowley. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion were excluded.
Time frame: Baseline through Week 16
Percentage of Participants Who Achieved a ≥1.5 g/dL Increase in Hb From Baseline Through Week 16
The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.
Time frame: Baseline through Week 16
Percentage of Participants Who Achieved a Hematopoietic Response
Hematopoietic response was defined as an increase in Hb of 1.5 g/dL from baseline or attaining a Hb of 11 g/dL. The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.
Time frame: Baseline through Week 16
Percentage of Participants Who Achieved a ≥2 g/dL Increase in Hb From Baseline Through Week 16
The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.
Time frame: Baseline through Week 16
Percentage of Participants Who Had an RBC Transfusion From Beginning of Week 5 (Day 29) to Week 16
Time frame: Week 5 to Week 16
| Milestone | Roxadustat |
|---|---|
| Started | 92 |
| Received at least 1 dose of study drug | 92 |
| Completed | 58 |
| Not completed | 34 |
| Withdrew: Withdrawal by subject | 12 |
| Withdrew: Adverse event | 1 |
| Withdrew: Progressive disease | 2 |
| Withdrew: Death | 13 |
| Withdrew: Other than specified | 6 |
Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1. All central lab assessments from Day 1 to end of treatment (EOT) or early termination (ET) were included in the evaluation of this endpoint. Hb values within 4 weeks after an RBC transfusion were excluded.
| g/dL | Roxadustat |
|---|---|
| Maximum Change in Hb Within 16 Weeks From Baseline Without Red Blood Cell (RBC) Transfusion | 2.47 ± 1.510 |
Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1. Mean Hb during treatment was computed using the mean area-under-the-curve trapezoid method, from Day 1 to EOT or ET Hb assessment.
| g/dL | Roxadustat |
|---|---|
| Mean Change in Hb Level From Baseline to Week 16 (Without RBC Transfusion) | 1.20 ± 1.012 |
Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1.
| g/dL | Roxadustat |
|---|---|
| Change at Week 9 | 1.43 ± 1.421 |
| Change at Week 13 | 2.15 ± 1.921 |
| Change at Week 16 | 2.52 ± 1.700 |
The 95% confidence interval (CI) was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.
| percentage of participants | Roxadustat |
|---|---|
| Percentage of Participants Who Achieved a ≥1 g/dL Increase in Hb From Baseline Through Week 16 | 82.0 (72.5 to 89.4) |
Median was calculated using Kaplan-Meier product limit method. 95% CI was calculated using the method of Brookmeyer and Crowley. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion were excluded.
| days | Roxadustat |
|---|---|
| Time to Achieve a ≥1 g/dL Increase in Hb From Baseline Through Week 16 | 41.0 (29.0 to 46.0) |
The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.
| percentage of participants | Roxadustat |
|---|---|
| Percentage of Participants Who Achieved a ≥1.5 g/dL Increase in Hb From Baseline Through Week 16 | 73.0 (62.6 to 81.9) |
Hematopoietic response was defined as an increase in Hb of 1.5 g/dL from baseline or attaining a Hb of 11 g/dL. The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.
| percentage of participants | Roxadustat |
|---|---|
| Percentage of Participants Who Achieved a Hematopoietic Response | 75.3 (65.0 to 83.8) |
The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.
| percentage of participants | Roxadustat |
|---|---|
| Percentage of Participants Who Achieved a ≥2 g/dL Increase in Hb From Baseline Through Week 16 | 60.7 (49.7 to 70.9) |
| percentage of participants | Roxadustat |
|---|---|
| Percentage of Participants Who Had an RBC Transfusion From Beginning of Week 5 (Day 29) to Week 16 | 14.5 |
Collected over Baseline up to Week 20. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roxadustat | 17/92 (18.5%) | 40/92 (43.5%) | 71/92 (77.2%) |
| Event | Roxadustat |
|---|---|
| Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/92 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/92 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/92 |
| AstheniaGeneral disorders | 3/92 |
| Disease progressionGeneral disorders | 3/92 |
| SepsisInfections and infestations | 3/92 |
| Mental status changesPsychiatric disorders | 3/92 |
| Deep vein thrombosisVascular disorders | 3/92 |
| AnaemiaBlood and lymphatic system disorders | 3/92 |
| Acute myocardial infarctionCardiac disorders | 2/92 |
| Event | Roxadustat |
|---|---|
| FatigueGeneral disorders | 23/92 |
| NauseaGastrointestinal disorders | 18/92 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 16/92 |
| DiarrhoeaGastrointestinal disorders | 14/92 |
| VomitingGastrointestinal disorders | 12/92 |
| Deep vein thrombosisVascular disorders | 11/92 |
| NeutropeniaBlood and lymphatic system disorders | 10/92 |
| ThrombocytopeniaBlood and lymphatic system disorders | 10/92 |
| ConstipationGastrointestinal disorders | 10/92 |
| Decreased appetiteMetabolism and nutrition disorders | 10/92 |
Intent-to-treat (ITT) population included all participants enrolled in the roxadustat treatment period and received at least 1 dose of study medication.
| Age, Continuous(years) | Roxadustat |
|---|---|
| Mean | 66.8 ± 10.44 |
| Sex: Female, Male(Participants) | Roxadustat |
|---|---|
| Female | 53 |
| Male | 39 |
| Ethnicity (NIH/OMB)(Participants) | Roxadustat |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 82 |
| Unknown or Not Reported | 3 |
| Race/Ethnicity, Customized(Participants) | Roxadustat |
|---|---|
| White | 76 |
| Black or African American | 12 |
| Asian | 3 |
| Other | 1 |
| Baseline Hemoglobin (Hb)(grams (g)/deciliter (dL)) | Roxadustat |
|---|---|
| Mean | 8.59 ± 0.956 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2019 to primary completion in Mar 2021, 19 months.
Results were first posted in Jun 2022, 1 year 2 months after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 19 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat